

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03390

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K45/00 A61K31/517 A61P35/00 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, EPO-Internal, PAJ, MEDLINE, EMBASE, COMPENDEX, SCISEARCH, CHEM ABS Data, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MAGNÉ N ET AL: "Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer" BRITISH JOURNAL OF CANCER 04 MAR 2002 UNITED KINGDOM, vol. 86, no. 5, 4 March 2002 (2002-03-04), pages 819-827, XP002256122 ISSN: 0007-0920 abstract; figures 3,5; table 4 page 821, column 1, last paragraph -column 2, paragraph 2 page 825, column 1, last line -page 826, column 1, paragraph 1 --- -/-</p>	1-14

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

30 September 2003

Date of mailing of the international search report

16/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Laffargue-Haak, T

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CIARDIELLO F ET AL: "ANTITUMOR EFFECT AND POTENTIATION OF CYTOTOXIC DRUGS ACTIVITY IN HUMAN CANCER CELLS BY ZD-1839 (IRESSA), AN EPIDERMAL GROWTH FACTOR RECEPTOR-SELECTIVE TYROSINE KINASE INHIBITOR"</p> <p>CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 6, no. 5, May 2000 (2000-05), pages 2053-2063, XP001009786</p> <p>ISSN: 1078-0432</p> <p>abstract</p> <p>page 2055, column 2, last paragraph -page 2057, column 1, paragraph 2; figures 3-8</p> <p>page 2061, column 1, paragraph 2 -page 2062, column 1, paragraph 1</p> <p>---</p>	1-14
Y	<p>HOLDEN S ET AL: "Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study."</p> <p>EUROPEAN JOURNAL OF CANCER, vol. 37, no. Supplement 6, October 2001 (2001-10), page S73</p> <p>XP002256123</p> <p>11th European Cancer Conference; Lisbon, Portugal; October 21-25, 2001, October, 2001</p> <p>ISSN: 0959-8049</p> <p>abstract</p> <p>---</p>	1-14
Y	<p>HENNEQUIN LAURENT F ET AL: "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors."</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 6, 14 March 2002 (2002-03-14), pages 1300-1312, XP002256124</p> <p>March 14, 2002</p> <p>ISSN: 0022-2623</p> <p>* see p. 1306-1307, ii. Inhibition of Endothelial Cell Proliferation ; vii. In Vivo Efficacy in Mouse ; Conclusions *</p> <p>abstract; figure 2; tables 4-6</p> <p>---</p> <p>-/-</p>	1-14

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	"Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR 'KDR1-TKI'), in a model of ZD1839 ('Iressa') resistance" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11), pages S60-S61, XP004403633 ISSN: 0959-8049 abstract -----	1-14
P,Y	MANLEY PAUL W ET AL: "Therapies directed at vascular endothelial growth factor." EXPERT OPINION ON INVESTIGATIONAL DRUGS. ENGLAND DEC 2002, vol. 11, no. 12, December 2002 (2002-12), pages 1715-1736, XP002256125 ISSN: 1354-3784 abstract -----	1-14